NCT02052882已完成2 期
An Open Label Phase II Study of Romiplostim for Chemotherapy Induced Thrombocytopenia
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 6
- 主要终点
- Percentage of Participants Who Achieved Platelet Counts of ≥ 100,000/mcL
研究概览
简要总结
This study is to determine if using weekly romiplostim injections will improve the patient's platelet count more effectively than simply waiting for the platelets to improve on its own, and if romiplostim will also allow the patient to receive at least 2 further cycles of chemotherapy without thrombocytopenia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients (18 years of age or greater) with active non-hematological cancer:
- •A. The patients have previously received a chemotherapy regimen including one or more of the following agents:
- •Nucleoside Analogue, including gemcitabine and fluorouracil
- •Carboplatin or cisplatin
- •Anthracycline
- •Alkylating agent
- •Other chemotherapy agents with thrombocytopenia as known common toxicity.
- •Patients who have not had any cytotoxic chemotherapy within 14 days of beginning the study.
- •Thrombocytopenia:.
- •A. Defined as platelet count <100,000/mcL.
- •B. The patient will have had at least 2 CBCs with platelet counts <100,000/mcL separated by at least 4 weeks, and no platelet count ≥100,000/mcL in the prior 6 week period, despite (1) delay, or (2) modification of chemotherapeutic regimen.
- •C. A platelet count of >100,000/mcL, that follows within 7 days of a platelet transfusion, will not make the patient ineligible, as long as one or more subsequent platelet counts confirms thrombocytopenia (<100,000/mcL).
- •D. Patients have undergone bone marrow aspirate and biopsy or peripheral blood test in the prior 3 months without evidence of leukemia or myelodysplasia by fluorescent in situ-hybridization (FISH) E. Dysplastic changes, based on morphology only, will not exclude the patient if FISH panel for MDS is normal.
- •4.KPS ≥ 50 or ECOG performance status ≤2 .
- •5.Ability to provide written informed consent.
排除标准
- •Patients with history of hematologic malignancies, including leukemia, myeloma, myeloproliferative disease, lymphoma, or myelodysplastic diseases.
- •Patients with known bone metastases, with evidence of corticol bone damage/lytic lesions/blastic lesions on standard imaging studies (CT/MR)
- •Anemia (Hgb <8.0 gm/dl) or leukopenia (absolute neutrophil count (ANC) <1,000/mcL). Use of red cell transfusions, erythropoietin, or G-CSF, as ordered by the managing oncology service, is acceptable and does not preclude participation.
- •Patients with underlying liver disease, such as cirrhosis or chronic hepatitis, and do not have primary or metastatic cancer in the liver will be excluded if ALT/AST >3X ULN or Total Bili >3X ULN. In the presence of primary or metastatic liver cancer, patients will be excluded if ALT/AST >5X ULN or Total Bili >5X ULN
- •Patients with a history of a prior symptomatic venous thrombotic event such, as DVT or pulmonary embolism and symptomatic arterial thrombotic events such as myocardial infarction, ischemic cerebral vascular accident or transient ischemic attack will be ineligible if they have not tolerated anticoagulation therapy. If patients remain on anticoagulation, or have completed the prescribed course of anticoagulation, they will be eligible for enrollment. A venous thrombotic event associated with a central venous catheter will not make the patient ineligible.
- •Serious concomitant medical condition that could interfere with the conduct of the clinical trial, such as unstable angina, renal failure requiring hemodialysis, or active infection requiring IV antibiotics
- •Pregnant women/lactating mothers
- •Patients unwilling to use contraception.
研究组 & 干预措施
Romiplostim
Experimental
All patients will begin weekly romiplostim at 2 mcg/kg, subcutaneously. The romiplostim dose will be titrated on weekly CBC/platelet counts. For titration purposes, the target platelet count is 150,000-200,000/mcL. Treatment can be held up to 16 days if a patient develops an intercurrent medical illness or symptom that is unrelated to study drug therapy.
Treatment may be held up to 20 days if the patient unavailable for non- medical reasons, such as vacation or travel.
干预措施: romiplostim (Biological)
结局指标
主要结局
Percentage of Participants Who Achieved Platelet Counts of ≥ 100,000/mcL
时间窗: within 3 weeks after treatment
The primary therapeutic response is assessed by the platelet count within 3 weeks of treatment.
次要结局
- Number of Participants Evaluated for Toxicity(1 year)
研究者
研究点 (6)
Loading locations...
相似试验
已完成
2 期
Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transplantation in People With Blood CancerNon-Hodgkin LymphomaHDT-AHCTMultiple MyelomaHodgkin LymphomaNCT04478123Memorial Sloan Kettering Cancer Center62
终止
2 期
Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving ChemotherapyRefractory Multiple MyelomaStage I Multiple MyelomaStage II Multiple MyelomaStage III Multiple MyelomaThrombocytopeniaNCT01676961NYU Langone Health5
终止
2 期
Romiplostim in Treating Hepatitis C-Infected Patients With ThrombocytopeniaHepatitis C InfectionThrombocytopeniaNCT01153919University of Southern California27
已完成
2 期
Using Romiplostim to Treat Low Platelet Counts During Chemotherapy in People With LymphomaLymphoma PatientsThrombocytopeniaNCT04673266Memorial Sloan Kettering Cancer Center11
终止
2 期
A Study of Romiplostim to Prevent Low Platelet Counts in Children and Young Adults Receiving Chemotherapy for Solid TumorsSolid TumorSolid Tumor, ChildhoodSolid CarcinomaNCT04671901Memorial Sloan Kettering Cancer Center2